Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

But Additional Survival Data Awaited

 
• By Jung Won Shin
  
clinical trials
Meeting Secondary Endpoints Will Increase Confidence In Tovecimig (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from South Korea

More from R&D